Biosimilars Forum Welcomes PBM Transparency Act
US Proposals Would See Spread Pricing Outlawed And Rebates Disclosed
Senators Maria Cantwell and Chuck Grassley have introduced a bill which would limit pharmacy benefit managers’ ability to engage in “unfair and deceptive” business practices, a move which has been welcomed by the Biosimilars Forum.
You may also be interested in...
As the dust settles after a wave of fresh adalimumab biosimilar launches, the US Biosimilars Forum’s executive director Julie Reed talks to Generics Bulletin about how other stakeholders need to step up to meet industry’s commitment to the sector – as well as how PBMs are distorting the market and streamlined regulation is needed to drive competition.
Cigna’s PBM, Express Scripts, is looking to “further align incentives across the pharmaceutical supply chain, consumers, and clients,” with a trio of new products available starting this summer.
The Association for Accessible Medicines has criticized draft legislation regarding US drug pricing negotiations for the impact proposed new laws could have on generic and biosimilar drugs.